A new trading day began on Friday, with Lipella Pharmaceuticals Inc (NASDAQ: LIPO) stock price up 9.33% from the previous day of trading, before settling in for the closing price of $0.45. LIPO’s price has ranged from $0.32 to $2.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 20.14% over the past five years. Meanwhile, its annual earnings per share averaged 28.57%. With a float of $5.16 million, this company’s outstanding shares have now reached $6.05 million.
Let’s look at the performance matrix of the company that is accounted for 7 employees. In terms of profitability, gross margin is 99.65%, operating margin of -396.88%, and the pretax margin is -391.01%.
Lipella Pharmaceuticals Inc (LIPO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lipella Pharmaceuticals Inc is 35.49%, while institutional ownership is 7.87%. The most recent insider transaction that took place on May 14 ’24, was worth 7,590. In this transaction insider of this company bought 10,000 shares at a rate of $0.76, taking the stock ownership to the 898,849 shares. Before that another transaction happened on Mar 18 ’24, when Company’s See remarks below. bought 30,000 for $0.79, making the entire transaction worth $23,649. This insider now owns 863,849 shares in total.
Lipella Pharmaceuticals Inc (LIPO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.57% per share during the next fiscal year.
Lipella Pharmaceuticals Inc (NASDAQ: LIPO) Trading Performance Indicators
Here are Lipella Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63 and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Lipella Pharmaceuticals Inc (LIPO)
Lipella Pharmaceuticals Inc (NASDAQ: LIPO) saw its 5-day average volume 7.76 million, a positive change from its year-to-date volume of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 70.03%. Additionally, its Average True Range was 0.06.
During the past 100 days, Lipella Pharmaceuticals Inc’s (LIPO) raw stochastic average was set at 14.54%, which indicates a significant decrease from 86.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.43% in the past 14 days, which was lower than the 167.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4327, while its 200-day Moving Average is $0.6725. Nevertheless, the first resistance level for the watch stands at $0.5177 in the near term. At $0.5410, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5808. If the price goes on to break the first support level at $0.4546, it is likely to go to the next support level at $0.4148. Assuming the price breaks the second support level, the third support level stands at $0.3915.
Lipella Pharmaceuticals Inc (NASDAQ: LIPO) Key Stats
With a market capitalization of 3.96 million, the company has a total of 7,606K Shares Outstanding. Currently, annual sales are 450 K while annual income is -4,620 K. The company’s previous quarter sales were 140 K while its latest quarter income was -940 K.
